

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule for Ages 5 Years and Older



COVID-19 vaccines are recommended for persons 5 years of age and older within the scope of the Emergency Use Authorization or Biologics License Application for the vaccine. The table below provides guidance for COVID-19 vaccination schedules based on age and medical condition. Detailed information can be found in CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States (link below).

Table 1. Immunization schedule for persons 5 years of age and older

Recipient Age	Product ^{†‡}	Persons Who ARE NOT Moderately or Severely Immunocompromised		Persons Who ARE Moderately or Severely Immunocompromised	
		Primary Series [§]	Booster Dose ^{¶¶}	Primary Series [§]	Booster Dose ^{¶¶}
Type: mRNA vaccine					
5–11 years	Pfizer-BioNTech Ages: 5–11 years Orange cap	2 doses. Separate: Dose 1 and 2 by at least 3 weeks **	At least 5 months ^{††} after Dose 2	3 doses. Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks.	Not recommended
12–17 years	Pfizer-BioNTech Ages: 12 years and older Gray cap or Purple cap	2 doses. Separate: Dose 1 and 2 by at least 3 - 8 weeks.**	At least 5 months ^{††} after Dose 2	3 doses. Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks.	At least 12 weeks after Dose 3
18 years and older	Pfizer-BioNTech Ages: 12 years and older Gray cap or Purple cap	2 doses. Separate: Dose 1 and 2 by at least 3 - 8 weeks.**	At least 5 months ^{††} after Dose 2	3 doses. Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks.	At least 12 weeks after Dose 3
	Moderna	2 doses. Separate: Dose 1 and 2 by at least 3 - 8 weeks.**	At least 5 months ^{††} after Dose 2	3 doses. Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks.	At least 12 weeks after Dose 3
Recipient Age	Product ^{†‡}	Persons Who ARE NOT Moderately or Severely Immunocompromised		Persons Who ARE Moderately or Severely Immunocompromised	
		Primary Series [§]	Booster Dose ^{¶¶}	Primary Series [§]	Booster Dose ^{¶¶}
Type: Viral vector vaccine					
18 years and older	Janssen ^{‡‡}	1 dose	At least 8 weeks after Dose 1	2 doses. Separate: Dose 1 and 2 by at least 28 days ^{§§} . Dose 2 MUST be a mRNA vaccine	At least 8 weeks after Dose 2

* Administer the appropriate COVID-19 vaccine product based on the recipient's age.

† COVID-19 vaccines may be administered on the same day as other vaccines. If multiple vaccines are administered at a single visit, administer each in a separate injection site.

‡ Administer doses as close as possible to the recommended interval. It is not necessary to restart the series if the dose is given after the recommended interval.

§ Complete the primary series using the same product. Every effort should be made to determine which vaccine product was received as the first dose. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.

¶ A different COVID-19 vaccine product than the primary series may be administered. An mRNA COVID-19 vaccine is preferred.

** An 8 week interval may be optimal for some people, including males 12-39 years of age because of the small risk of myocarditis associated with mRNA COVID-19 vaccines. Vaccine effectiveness may also be increased with an interval longer than 3 (or 4 depending on document) weeks. See Interim Clinical Considerations for COVID-19 Vaccines (link below) for detailed information.

†† Calendar months

‡‡ mRNA COVID-19 vaccines are preferred over the Janssen COVID-19 Vaccine for all vaccine-eligible people. However, the Janssen COVID-19 Vaccine may be offered in some situations, see Interim Clinical Considerations for COVID-19 Vaccines (link below) for detailed information.

§§ Administer Moderna or Pfizer-BioNTech COVID-19 Vaccine only, which are allowed under Emergency Use Instructions (EUI) for this dose. Janssen COVID-19 Vaccine is not under EUI for this dose.

CDC Resources

CDC COVID-19 Vaccine clinical training and materials at: www.cdc.gov/vaccines/covid-19/info-by-product/index.html

CDC Interim clinical considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States at:

www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for Ages 5 Years and Older



Table 2. COVID-19 Vaccine Products Summary

Product	Age Indications	Diluent	Dosage (amount injected)	
Type: mRNA vaccine				
Pfizer-BioNTech Orange cap and bordered label	5 - 11 years	1.3 mL 0.9% sodium chloride (normal saline, preservative-free)	Doses 1 and 2	0.2 mL
			Dose 3*	0.2 mL
			Booster dose	Not recommended
Pfizer-BioNTech Gray cap and bordered label	12 years and older	NONE	Doses 1 and 2	0.3 mL
			Dose 3*	0.3 mL
			Booster dose	0.3 mL
Pfizer-BioNTech Purple cap	12 years and older	1.8 mL 0.9% sodium chloride (normal saline, preservative-free)	Doses 1 and 2	0.3 mL
			Dose 3*	0.3 mL
			Booster dose	0.3 mL
Moderna Red cap	18 years and older	NONE	Doses 1 and 2	0.5 mL
			Dose 3*	0.5 mL
			Booster dose	0.25 mL
Product	Age Indications	Diluent	Dosage (amount injected)	
Type: Viral Vector Vaccine				
Janssen[†] Blue Cap	18 years and older	NONE	Dose 1	0.5 mL
			Dose 2*	Dose 2 Administer mRNA vaccine only ‡
			Booster dose	0.5 mL

* For moderate or severely immunocompromised persons only

† mRNA vaccines are preferred.

‡ Additional dose for moderate or severely immunocompromised persons only: Administer Moderna or Pfizer-BioNTech COVID-19 Vaccine ONLY. Administer the correct product based on the recipient's age. If administering Moderna COVID-19 Vaccine, administer 0.5 mL.

CDC Resources

CDC COVID-19 Vaccine clinical training and materials at: www.cdc.gov/vaccines/covid-19/info-by-product/index.html

CDC Interim clinical considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States at www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series